Autoimmunity BioSolutions, a Houston, TX-based biotechnology firm advancing immuno-corrective therapies, raised $2M in Seed funding.
The spherical was led by Eos BioInnovation, with participation from Alexandria Enterprise Investments, Unbiased Capital and others.
The corporate intends to make use of the funds to boost the event of its lead program, which consisted of monoclonal antibodies particularly focusing on sIL7R whereas sparing membrane-bound IL7R.
Led by Eugene Williams, CEO, and Gaddiel Galarza-Munoz, CSO, Autoimmunity BioSolutions (ABS) is a seed-stage biotech creating a next-generation, immuno-corrective antibody remedy for therapy of autoimmune illnesses to revive regular immune operate. This remedy is focused to a genetically-defined subpopulation of autoimmune illness sufferers marked by a extremely prevalent genetic variant (SNP) related to elevated danger and severity of varied autoimmune illnesses. This immuno-corrective strategy to autoimmune illness therapy is extremely differentiated from present requirements of care that depend on immunosuppressive mechanisms, and has broad potential to deal with quite a few autoimmune illnesses.
Commenting on the information, Gene Williams stated: “I’m thrilled to be a part of this excellent workforce within the effort to develop therapies that could possibly be transformative for a lot of sufferers with autoimmune illness and need to thank our excellent group of buyers for his or her assist. ABS is within the forefront of a subsequent era of transformative therapies correcting the genetic drivers of illness in a genetically-defined inhabitants. Based mostly on the recognized epidemiology and biology, we count on our therapies could have worth in extreme illness populations which might be difficult to deal with, comparable to progressive MS or lupus nephritis, the place we’d see environment friendly early proof of idea and probably a speedy path to approval. As well as, we plan to collaborate with leaders within the subject to discover the chance that genetically-defined immuno-corrective remedy comparable to ours, with its doubtless security benefits over present requirements of care, may emerge as first line concomitant remedy for all sufferers with the SNP, to mitigate danger of illness development in addition to deal with extreme illness, and probably to scale back the necessity for immunosuppression.”
FinSMEs
28/11/2024
